Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07458113 · ClinicalTrials.gov registry record · Phase 2
Sac-TMT for Active TNBC Brain Metastases
A Phase 2 study, sponsored by Yale University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT07458113 is a Phase 2 study that has not yet begun recruiting, run by Yale University. The registered enrollment target is 20 participants.
The verdict
NCT07458113, a Phase 2 study, has not yet begun recruiting, sponsored by Yale University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a multi-site prospective single-arm open-label phase 2 clinical trial including 20 participants with metastatic TNBC and active brain metastases to be treated with sacituzumab tirumotecan 4 mg/kg IV on Days 1, and 15 of every 28-day cycle until disease progression, unacceptable toxicities, consent withdrawal, or death.
Interventions
- DRUG Sacituzumab tirumotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-05 |
| Est. Completion | 2029-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07458113
The ClinicalTrials.gov registry entry for NCT07458113 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sacituzumab tirumotecan is the first listed.
NCT07458113 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07458113 about?
NCT07458113 is a clinical study titled "Sac-TMT for Active TNBC Brain Metastases". This is a multi-site prospective single-arm open-label phase 2 clinical trial including 20 participants with metastatic TNBC and active brain metastases to be treated with sacituzumab tirumotecan 4 mg/kg IV on Days 1, and 15 of every 28-day cycle until disease progression, unacceptable toxicities, c...
What is the current status of trial NCT07458113?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2026-05. Estimated completion is 2029-05.
What interventions are being tested in trial NCT07458113?
The interventions under investigation include: Sacituzumab tirumotecan (DRUG).
Who is sponsoring clinical trial NCT07458113?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.